Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04603-3
In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.
